We did not prioritize the genes based on PCa-related biological pathways or patient outcomes, however, our signature also includes three genes (CENPF, DLGAP5, and PRC1) represented in the cell cycle progression score [3], (Prolaris®), one gene (ANO7) in the metastasis-based DecipherTM panel [5], two genes (ANO7 and ESM1) in the PCa recurrence-based signature [6], and two genes (CENPE and CST2) in the signature for ML progression previously developed by our group [7]. The gene discussed is ESM1; the disease is posterior cortical atrophy.